Ann: Opthea reports positive data from Phase 1 wet AMD Trial-OPT.AX, page-5

Drugs in this area are judged successful if they prevent deterioration. On that measure the results albeit from a small sample are impressive

"Overall, a majority of patients (16/19 evaluable at week 12) maintained or gained vision by week 12 compared to baseline and the other 3 patients that all received combination OPT-302 + Lucentis® therapy did not lose more than 3 letters (range -2 to -3 letters). The mean gain in visual acuity overall from baseline at week 12 in treatment naïve patients who received OPT-302 + Lucentis® was 16.5 letters (n=4) and 9.5 letters in the 2 mg OPT-302 + Lucentis® dose cohort (n=2). The mean visual acuity gain from baseline at week 12 in patients who showed a sub-optimal response to prior anti-VEGF-A therapy was 4 letters with combination OPT-302 + Lucentis® (n=10 evaluable patients; mean number of prior treatment injections = 10.5, range 3 – 55)."

So what`s it worth?? OPT 302  from these results improves patients treated for VEGF A alone and I`m sure Lucentis and Opthotech will have taken note.